Fig. 5From: Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practiceOverall survival (A,B,C) and progression-free survival (D,E,F) depending on baseline EORTC QLQ-C30 global score (A,D), baseline Karnofsky Index (B,E), and weight loss in the previous 3 months (C,F). Survival is presented as median (95% CI); p-values correspond to the Log-rank test for inter-curve differencesBack to article page